Objective. We evaluated the prognostic significance of CD44 isoform CD44 V6
in endometrial cancer.
Method. Immunohistochemistry was used to determine the expression of CD44 V
6 in 78 randomly selected endometrial cancer specimens.
Results. CD44 V6 was detected in 53% (41/78) of the tumor samples. Clinicop
athological evaluation revealed an inverse correlation with CD44 V6 express
ion and conventional poor prognosticators such as lower segment involvement
, nuclear and structural grade, myometrial invasion, serosal involvement, l
ymph-vascular space invasion, and adnexal metastasis. Furthermore, the CD44
V6-negative group was found to be associated have a higher recurrence rate
and a shorter disease-free survival.
Conclusion. These findings indicate that absence of CD44 V6 expression in c
ases of endometrial cancer might be coupled with a more aggressive course.
(C) 2001 Academic Press.